About VBI Vaccines (TSE:VBV)
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Sector: N/A
- Symbol: TSE:VBV
- CUSIP: N/A
- Web: www.vbivaccines.com
- Trailing EPS: C($0.91)
- Net Margins: -2,620.06%
- Return on Equity: -49.79%
- Return on Assets: -38.26%
- Outstanding Shares: 63,805,000
Frequently Asked Questions for VBI Vaccines (TSE:VBV)
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VBV."
When will VBI Vaccines make its next earnings announcement?
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Lundin Gold (LUG), Source Energy Services Ltd (SHLE), Klondex Mines Ltd (KDX), Mountain Province Diamonds (MPVD), Slate Retail REIT (SRT.UN), Capstone Mining Corp (CS), Uranium Participation Corp (U), Golden Star Resources (GSC), Stornoway Diamond (SWY), Sprott (SII), Sandvine (SVC), Aimia (AIM), Dream Industrial Real Estate Invest Trst (DIR.UN), Crius Energy Trust (KWH.UN), Heroux Devtek (HRX), CanWel Building Materials Group Ltd (CWX), Cardinal Energy Ltd (CJ) and Altius Minerals (ALS).
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Steven D. Rubin, Chairman of the Board
- Curtis A. Lockshin, Chief Executive Officer, Director
- Athena Kartsaklis, Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller (Age 52)
- Shayla Forster, Corporate Secretary
- Dmitry Genkin, Director
- Kate Inman, Director
- Adam Logal, Director
- Ran Nussbaum, Director (Age 44)
- David S. Rector, Additional Independent Director (Age 68)
How do I buy VBI Vaccines stock?
Shares of VBI Vaccines and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBI Vaccines stock can currently be purchased for approximately C$5.80.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of C$290.28 million.
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 3rd St Ste 2241, CAMBRIDGE, MA 02142-1259, United States. The company can be reached via phone at +1-617-8303031.
MarketBeat Community Rating for VBI Vaccines (TSE VBV)MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for VBI Vaccines (TSE:VBV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for VBI Vaccines (TSE:VBV)
Analysts' Ratings History for VBI Vaccines (TSE:VBV)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for VBI Vaccines (TSE:VBV)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for VBI Vaccines (TSE:VBV)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for VBI Vaccines (TSE:VBV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for VBI Vaccines (TSE VBV)
Insider Trades by Quarter for VBI Vaccines (TSE VBV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/21/2017||Jeffrey Royston Baxter||Director||Buy||10,000||C$3.22||C$32,200.00|
Latest Headlines for VBI Vaccines (TSE VBV)
Financials are not available for this stock.
VBI Vaccines (TSE VBV) Chart for Tuesday, November, 21, 2017